HealthLinx's Cancer Test on Market Soon (Australia)
This article was originally published in PharmAsia News
Executive Summary
Healthlinx Ltd., one of Australia's leading diagnostics developers, hopes to market a new blood test for ovarian cancer by the second quarter of 2008. The new testing method, called OvPlex, recently showed promising results during a Phase II clinical trial. OvPlex measures five different biomarkers in the blood, making it more sensitive and more accurate than most of those currently on the market. The company hopes to make it available domestically as well as submitting it for approval in the United States, Asia, and Europe. (Click here for more - May Require Free Registration